People's Daily health client Qiu Yue
On December 15, BeiGene announced the completion of its initial public offering on the Sci-Tech Innovation Board of the Shanghai Stock Exchange, becoming the first biotechnology company to be listed on the NASDAQ Composite Index, the Hong Kong Stock Exchange and the Sci-Tech Innovation Board of the Shanghai Stock Exchange.
Since the beginning of this year, benefiting from the reform of the IPO system and the encouragement of relevant pharmaceutical policies, many innovative pharmaceutical companies have flocked to the capital market. The Health Times reporter found that just halfway through December, at least 5 pharmaceutical companies have been successfully listed.
According to the data of Tonghua Shunifind, as of December 15, 34 biopharmaceutical companies have been listed on the Science and Technology Innovation Board during the year, and two companies, Nanmo Biologics and Chunli Medical, have obtained listing permits from the CSRC.
BeiGene: The first pharmaceutical company listed in three places to achieve a "breakthrough of zero" for China's anti-cancer drugs to go to sea
On December 15, BeiGene landed on the Science and Technology Innovation Board, becoming the world's first biomedical company to be listed in the United States, Hong Kong and A-shares. On the first day of listing on the Science and Technology Innovation Board, BeiGene's opening price was 176.96 yuan.
BeiGene R&D center, courtesy of the company.
Founded in 2010, BeiGene is a global biotechnology company focused on developing innovative medicines. According to China Securities Network, as of November 2021, BeiGene has a total of 48 commercial products and clinical stage drug candidates, including 10 commercial stage drugs, 2 declared drug candidates and 36 clinical stage drug candidates.
BeiGene has successfully listed 3 blockbuster self-developed drugs: BTK small molecule inhibitor Baiyueze (Zebutinib capsules), anti-PD-1 monoclonal Bai zean (tirelizumab injection) and PARP inhibitor Baihuize (Pamipalis capsules). Among them, the BTK inhibitor Baiyueze was approved by the FDA for accelerated listing and was approved in the United States in November 2019, achieving a "breakthrough of zero" in China's anti-tumor innovative drugs.
Di Zhe Pharmaceutical: the "youngest" listed company in A shares
On December 10, Di Zhe Pharmaceutical was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, and Di Zhe Pharmaceutical, founded in October 2017, became the "youngest" listed company in the A-share market.
The picture is from the official website of Di Zhe Pharmaceutical.
In 2006, Zhang Xiaolin, then a senior scientist and global vice president of AstraZeneca, established the AstraZeneca China Innovation Center and developed it into one of AstraZeneca's four major global R&D centers. In 2017, in order to deepen the empowerment of localization in the Chinese market, Dizhe Pharmaceutical was born.
According to the Shanghai Securities News, although AstraZeneca is the largest shareholder of Dizhe Pharmaceutical, according to Zhang Xiaolin, chairman and general manager of Dizhe Pharmaceutical, Di zhe Pharmaceutical does not have a dependence on AstraZeneca. "Di zhe pharma's goal is to launch the world's first-in-class and breakthrough potential treatments to fill the unmet clinical needs."
As of June 30, 2021, the Company's R&D pipeline portfolio has four innovative drugs in the clinical phase and used for multiple indications, as well as several innovative drug candidates in the preclinical research phase. Among them, the fastest progress is the world's first specific JAK1 inhibitor DZD4205 for clinical research on peripheral T-cell lymphoma disease, and a blockbuster lung cancer drug DZD9008.
Kai Laiying: The market value exceeds 100 billion! China's maximal drug commercialization outsourcing production giant
On December 10, Gloria Ind was listed on the Main Board of the Hong Kong Stock Exchange and traded. This is the second listing of Gloria Ingen, as early as five years ago landed in the A-share of Gloria Pharmaceutical, is now the largest chemical drug commercial outsourcing production (CDMO) giant, with a market value of more than 100 billion yuan.
Gloria Ying Full Continuity Response Laboratory, picture from Gloria Ying's official website.
According to China Net, as a world-leading, technology-driven CDMO company, Kailaiying mainly provides one-stop services and solutions throughout the whole cycle of drug development and production.
According to the official website of Gloria Pharmaceutical Group, GloriaIn is the world's fifth largest innovative drug API CDMO, as well as China's largest commercialization stage chemical drug CDMO. According to the prospectus, CallaIne has now expanded its CDMO capabilities to include new drug categories such as peptides, oligonucleotides, monoclonal antibodies, etc., as well as pharmaceutical formulations, biosynthesis and clinical CRO solutions.
Beihai Kangcheng: Focus on rare diseases and rare tumor special drugs
On December 10, Beihai Kangcheng was officially listed on the Hong Kong Stock Exchange. Founded in 2012, the company is a China-based biomedical company focusing on commercialized rare disease drugs and rare tumor special drugs.
The listing meeting of Beihai Kangcheng Hai Ruisi was held on the platform of the 2020 China Rare Disease Conference.
According to the prospectus, Beihai Kangcheng has built a research and development pipeline with 13 products, including 3 listed products, 4 candidate drugs in the clinical stage, 1 project in the clinical trial preparation stage, 2 projects in the pre-clinical stage, and 3 gene therapy projects in the pilot identification stage. Beihai Kangcheng will mainly use the funds raised to support the research and development of core drug candidate CAN008 and cmC; support the main products and candidate products in the pipeline; support the non-gene therapy products and candidate products in the pipeline; and support the research and development of CAN201, CAN202 and other gene therapy projects.
According to the official website of Beihai Kangcheng, the company is currently developing CAN008, a core product for the treatment of polymorphic glioblastoma (GBM), and was approved to conduct a first-line Phase 2 clinical trial in patients with glioblastoma in China in April 2021. In addition, Beihai Kangcheng is also investing in next-generation gene therapy technology and is developing drugs for the treatment of rare diseases such as Fabrai disease and Pompeii disease.
Gushengtang: The "first share" of chain TCM, innovative medical association grassroots cooperation
On December 10, Gushengtang Holdings Limited was successfully listed on the main board of the Hong Kong Stock Exchange, becoming the first stock of the chain of Chinese medicine halls and Chinese medicine medical services.
According to the official website of Gushengtang Chinese Medicine, Gushengtang Chinese Medicine is a Chinese medicine chain management group, integrating traditional Chinese medicine medicine, traditional Chinese medicine teaching, traditional Chinese medicine promotion, etc., headquartered in Guangzhou, expanding Beijing, Guangzhou, Shenzhen, Foshan, Zhongshan, Wuxi, Nanjing, Fuzhou, Shanghai, Suzhou, Kunshan, Chengdu, Ningbo and other regions, the platform service covers 56 cities across the country.
According to the Economic Information Daily, Gushengtang has carried out medical cooperation in Beijing, Shanghai, Guangzhou and other places, covering a number of departments such as oncology, cardiovascular, endocrinology, gynecology, respiratory, dermatology, spleen and stomach diseases, nephrology, pediatrics, rheumatology, psychosomatic medicine, otolaryngology and so on. Tu Zhiliang, founder and chairman of Gushengtang Traditional Chinese Medicine, said that Gushengtang has established medical associations and specialties with a number of hospitals to build cooperation, and invited Chinese medicine masters and provincial and municipal famous old Chinese medicine doctors to grass-roots outpatient clinics, which not only solves the problem of the "last kilometer" of patients to see a doctor, but also obtains a higher reimbursement ratio and effectively improves the sense of access and happiness of medical treatment.
Editor: Qiu Yue